-44.8%
PCG vs MRNA
+806.0%
-850.8%
-85.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.7% | +1.3% | +0.4% | +1.7% |
| 7D | +7.5% | -13.8% | +21.3% | +7.7% |
| 30D | +5.8% | -17.7% | +23.4% | +6.0% |
| 3M | -20.7% | +14.3% | -35.0% | -21.0% |
| 6M | -14.5% | +336.0% | -350.4% | -18.2% |
| YTD | -12.4% | +575.9% | -588.3% | -17.6% |
| 1Y | -10.2% | +724.4% | -734.5% | -16.1% |
| 3Y | -20.5% | +160.8% | -181.3% | -24.2% |
| 5Y | +15.0% | -24.4% | +39.5% | +10.4% |
| All | -44.8% | +806.0% | -850.8% | -48.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling